Catalyst Pharmaceuticals (NASDAQ:CPRX – Get Free Report) was upgraded by stock analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued on Friday. Several other analysts also recently commented on CPRX. Oppenheimer reaffirmed an “outperform” rating and set a $29.00 target price on shares of Catalyst Pharmaceuticals in a […]
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Average Rating of "Buy" by Brokerages themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives $26.43 Average Price Target from Analysts theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Get Free Report) have received an average recommendation of “Buy” from the five brokerages that are covering the stock, Marketbeat Ratings reports. Five investment analysts have rated the stock with a buy rating. The average 12 month target price among brokers that have issued a report on the […]
Oppenheimer reiterated their outperform rating on shares of Catalyst Pharmaceuticals (NASDAQ:CPRX – Free Report) in a research report report published on Wednesday, Benzinga reports. They currently have a $29.00 price target on the biopharmaceutical company’s stock. A number of other equities research analysts have also weighed in on the company. Citigroup began coverage on Catalyst […]